D in median PFS and median OS outcomes similar to these
D in median PFS and median OS final results comparable to these observed in MET-negative patients getting erlotinib alone. ThisJOURNAL OF CLINICAL ONCOLOGYOnartuzumab Plus Erlotinib in Advanced NSCLCsuggests that the…